Last Updated on December 22, 2024 by The Health Master
Form 483
Lupin Limited, a leading global pharmaceutical company, recently announced the outcome of a pre-approval inspection conducted by the US Food and Drug Administration (USFDA) at its Somerset, New Jersey manufacturing facility y means of 6 observations vide Form 483.
This inspection, specifically designed for facilities seeking approval to manufacture high-visibility drugs, is a critical step for Lupin’s expansion in the US market.
Inspection Findings and Form 483
The USFDA inspection, which took place from May 7th to May 17th, 2024, resulted in the issuance of a Form 483.
This form details six observations identified by USFDA inspectors during the visit.
While the specific nature of these observations remains undisclosed, a Form 483 typically indicates potential violations of USFDA regulations governing Good Manufacturing Practices (GMP) for drugs.
These regulations ensure the safety, quality, and efficacy of pharmaceutical products reaching American consumers.
Lupin’s Response and Next Steps
In a statement to the Bombay Stock Exchange (BSE), Lupin acknowledged the USFDA’s findings and emphasized its commitment to regulatory compliance.
The company has assured investors and stakeholders that it is comprehensively addressing all six observations outlined in the Form 483.
A detailed corrective action plan (CAP) is being formulated to ensure swift resolution of the identified issues.
This plan will be submitted to the USFDA within the stipulated timeframe, demonstrating Lupin’s commitment to meeting the agency’s high standards.
Looking Forward
A successful response to the USFDA’s observations is crucial for Lupin’s continued operations in the US market.
By addressing the identified concerns promptly and effectively, Lupin can ensure its Somerset facility meets the rigorous standards for manufacturing high-quality pharmaceutical products.
This, in turn, paves the way for the company to expand its offerings and contribute to the well-being of patients in the United States.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA inspection: With zero observation at Indoco Remedies
USFDA issued Form 483 with 1 observation to Cipla
USFDA Inspection with Positive EIR to Alembic Pharma
USFDA Inspection: At Aurobindo Pharma Arm with 7 USFDA Observations
Gujarat FDCA and IDMA Join Forces for GMP Compliance Training
Relief for Medical Devices: CDSCO Grants 3-Month Extension
USFDA approval granted for Edaravone Injection
Drug recall: Dr Reddy’s, Sun Pharma, Aurobindo recall these drugs due to this reason
NPPA revised Ceiling price of 6 scheduled formulations: May 2024
Indian Pharma Industry Gears Up to comply Revised Schedule M
CDSCO: Timely pay retention fee to Avoid Disruption in Medical Device licenses
NPPA fixed retail price of 4 formulations: May 2024
FSSAI Takes Action: Popular Beverage Mixes Reclassified on E-commerce Platforms
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
